EUCTR2019-002364-27-AT进行中（未招募）1 期
An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEoadjuvant therapy for HER2-positive early breast cancer - ATHENE
ABCSG (Austrian Breast & Colorectal Cancer Study Group)0 个研究点目标入组 58 人开始时间: 2019年11月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Patient / Disease Specifics
- •(1) Signed informed consent obtained prior to any study specific assessments and procedures which are not performed as part of standard of care
- •(2) Female patients, age = 18 years at the time of signing informed consent form (ICF)
- •(3) Histologically confirmed invasive, unilateral adenocarcinoma of the breast with the following characteristics:
- •- cT1c-4a-d, N0–3, M0 per AJCC (American Joint Committee on Cancer) Breast Cancer Staging version 8
- •- In the case of a multifocal tumor (defined as the presence of two or more foci of cancer within the same breast quadrant), the largest lesion must be > 1 cm and designated as the target” lesion for all subsequent tumor evaluations
- •- In the case of a multicentric tumor (defined as the presence of two or more foci of cancer within different quadrants), the largest lesion must be > 1 cm and designated as the target” lesion for all subsequent tumor evaluations
- •- histologically confirmed HER2 positivity; HER2 measurement to be assessed locally as 3+ by immunohistochemistry or 2+ by immunohistochemistry with HER2 amplification by In Situ Hybridization (ISH) according to the ASCO/CAP guideline
- •- If biopsies were taken from more than one focus, all histologically confirmed invasive breast cancer foci have to be HER2 positive. In case of a multicentric tumor, at least two foci in different breast quadrants have to be histologically confirmed HER2 positive breast cancer
- •- Hormone receptor positive or negative tumors
- •(4) Tumor tissue from FFPE core-needly biopsy of breast tumor measuring at least 3x1 mm must be transmitted to a central sample repository and feedback on central TIL assessment must be available prior to randomization
- •(5) Neoadjuvant chemotherapy indicated (at the discretion of the investigator)
- •(6) ECOG performance status 0-1
- •(7) In women of childbearing potential, urine or serum pregnancy test must be negative within 28 days prior to randomization. In postmenopausal women or hysterectomized patients, pregnancy tests do not need to be performed
- •(8) Adequate left ventricular ejection fraction (LVEF) at baseline, defined as LVEF = 55 % by either echocardiogram or MUGA
- •Baseline body function specifics
- •(9) ANC = 1.5 x 10^9/L (1500/µL) without granulocyte colony-stimulating factor support
- •(10) Lymphocyte count = 0.5 x 10^9/L (500/µL)
- •(11) Platelet count = 100 x 10^9/L (100,000/µL) without transfusion
- •(12) Hemoglobin = 90 g/L (9 g/dL). Patients may be transfused to meet this criterion
- •(13)For patients not receiving therapeutic anticoagulation: INR or aPTT = 1.5 x ULN. For patients receiving therapeutic anticoagulation: stable anticoagulant regimen.
- •(14)Aspartate amino transferase (AST), alanine amino transferase (ALT), and alkaline phosphatase (ALP) = 2.5 x ULN
- •(15)Serum bilirubin =1.5 x ULN with the following exception: Patients with known Gilbert’s syndrome: serum bilirubin level = 3 x ULN
- •(16)Serum creatinine = 1.5 x ULN AND creatinine clearance = 50 mL/min (calculated using the Cockcroft-Gault formula)
- •(17)Ability to understand and fill out PRO questionnaires
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 29
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 29
排除标准
- •(1) Metastatic or locally advanced disease (without loco-regional treatment options with curative intention)
- •(2) Patient receiving any prior cancer therapy for invasive breast cancer and/or the same disease
- •(3) Bilateral invasive breast cancer
- •(4) Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti- Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- •(5) History of other malignancy; patients who have been disease-free for 5 years or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible
- •(6) Pregnant or lactating women
- •(7) Serious medical or psychiatric disorders that would interfere with the patient’s safety or informed consent (at the discretion of the investigator)
- •(8) Clinically significant cardiovascular disease, requiring medication during the study and which might interfere with regularity of the study treatment, or not controlled by medication (at the discretion of the investigator)
- •(9) Clinically relevant, active bacterial, viral or fungal infection (at the discretion of the investigator)
- •(10)History of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, uncontrolled inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis. Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible. Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible as well
- •(11) Prior allogeneic stem cell or solid organ transplantation
- •(12)Concurrent participation in another clinical trial with the same primary endpoint and/or concurrent participation in another clinical trial with an investigational product
- •(13)Known hypersensitivity to the study drugs
- •(14)Active tuberculosis
- •(15)Patients receiving live, attenuated vaccine within 4 weeks prior to Cycle 1 Day 1 (= V1) AND not fit for study participation as per investigator’s assessment.
- •(16)Treatment with therapeutic oral or iv antibiotics within 2 weeks prior to randomization
- •(17)Known uncontrolled HIV, HCV and HBV infection
研究者
相似试验
尚未招募
不适用
A Phase 1, Randomized, Open-label, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled syringe of CT-P47 in Healthy SubjectsKCT0007816Celltrion268
进行中（未招募）
1 期
A study to investigate the pharmacokinetics and safety with a single dose of SAR442970 in healthy adult Japanese participantsJPRN-jRCT2071230056Tanaka Tomoyuki12
已完成
2 期
A single-center, randomized, open-label, two-arm study to evaluate the ovarian function inhibition of a monophasic combined oral contraceptive (COC) containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP) and a monophasic COC containing 20 mcg ethinylestradiol (E4)/3 mg drospirenone (Yaz®), administered orally once daily in a 24/4 day regimen for three consecutive cyclesNL-OMON43032Estetra SPR80
已完成
4 期
Study to assess efficacy & safety of doxofylline 400 mg twice daily versus doxofylline 800 mg ER once daily in the treatment of chronic obstructive pulmonary disease.CTRI/2008/091/000154German Remedies Division, Cadila Healthcare Limited
进行中（未招募）
不适用
A randomized two-arm, multicenter, open-label phase III study of BMS-354825 administered orally at a dose of 70 mg twice daily or 140 mg once daily in subjects with chronic myeloid leukemia in accelerated phase or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec). Revised protocol 06, incorporating administrative letters 01, 02, and 03 and amendments 01, 02, 03, 04 (v1.0 dated 28 Feb 2008) and 05 (v1.0 dated 19 Dec 2008).Subjects with chronic myeloid leukemia in accelerated phase or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate.MedDRA version: 14.1Level: HLGTClassification code 10024324Term: LeukaemiasSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2005-001169-32-ITBRISTOL-M.SQUIBB540